UY28501A1 - Compuestos químicos - Google Patents

Compuestos químicos

Info

Publication number
UY28501A1
UY28501A1 UY28501A UY28501A UY28501A1 UY 28501 A1 UY28501 A1 UY 28501A1 UY 28501 A UY28501 A UY 28501A UY 28501 A UY28501 A UY 28501A UY 28501 A1 UY28501 A1 UY 28501A1
Authority
UY
Uruguay
Prior art keywords
chemical compounds
dihifroxyhept
hmg
methylsulfonyl
pyrimidin
Prior art date
Application number
UY28501A
Other languages
English (en)
Inventor
Booth Rebecca Jane
Cittern Peter Anthony
Crabb Jeffrey Norman
Horbury John
Jones David Wyn Calvert
Original Assignee
Astrazeneca Uk Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34276833&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UY28501(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GB0321127A external-priority patent/GB0321127D0/en
Priority claimed from GB0404859A external-priority patent/GB0404859D0/en
Application filed by Astrazeneca Uk Ltd filed Critical Astrazeneca Uk Ltd
Publication of UY28501A1 publication Critical patent/UY28501A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/42—One nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Abstract

Se describen dos formas polimórficas de sal de calcio bis (E)-7-(4-(4-fluorofenil)-6-isopropil-2- (metil(metilsulfonil) amino)pirimidin-5-il) (3R, 5S) -3,5-dihifroxihept -6- acido enoico); los procesos para obtenerlas y su uso como inhibidores de HMG Co A reductasa.
UY28501A 2003-09-10 2004-09-07 Compuestos químicos UY28501A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0321127A GB0321127D0 (en) 2003-09-10 2003-09-10 Chemical compounds
GB0404859A GB0404859D0 (en) 2004-03-04 2004-03-04 Chemical compound

Publications (1)

Publication Number Publication Date
UY28501A1 true UY28501A1 (es) 2005-04-29

Family

ID=34276833

Family Applications (1)

Application Number Title Priority Date Filing Date
UY28501A UY28501A1 (es) 2003-09-10 2004-09-07 Compuestos químicos

Country Status (32)

Country Link
US (4) US20060293355A1 (es)
EP (1) EP1663989B1 (es)
JP (1) JP2007505090A (es)
KR (1) KR20070019943A (es)
CN (1) CN1878760B (es)
AR (1) AR045628A1 (es)
AT (1) ATE428701T1 (es)
AU (1) AU2004270467B8 (es)
BR (1) BRPI0414236A (es)
CA (1) CA2537962C (es)
CO (1) CO5670355A2 (es)
CY (1) CY1109173T1 (es)
DE (1) DE602004020640D1 (es)
DK (1) DK1663989T3 (es)
ES (1) ES2324042T3 (es)
HK (1) HK1090361A1 (es)
HR (1) HRP20090335T1 (es)
IL (1) IL174073A (es)
IS (1) IS2689B (es)
MX (1) MXPA06002761A (es)
MY (1) MY142615A (es)
NO (1) NO336358B1 (es)
NZ (1) NZ545785A (es)
PL (1) PL1663989T3 (es)
PT (1) PT1663989E (es)
RU (1) RU2363697C2 (es)
SA (1) SA04250297B1 (es)
SI (1) SI1663989T1 (es)
TW (1) TWI370817B (es)
UA (1) UA85062C2 (es)
UY (1) UY28501A1 (es)
WO (1) WO2005023779A1 (es)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0003305D0 (en) 2000-02-15 2000-04-05 Zeneca Ltd Pyrimidine derivatives
GB0011120D0 (en) 2000-05-09 2000-06-28 Avecia Ltd Process
NL1015744C2 (nl) 2000-07-19 2002-01-22 Dsm Nv Werkwijze voor de bereiding van 2-(6-gesubstitueerde-1,3-dioxan-4-yl) azijnzuurderivaten.
BR0211072A (pt) 2001-07-13 2004-12-14 Astrazeneca Uk Ltd Processo para preparar um composto, composto, e, método para a preparação de um composto
EP1323717A1 (en) 2001-12-27 2003-07-02 Dsm N.V. Process for the preparation of 2-(6-Substituted-1,3-Dioxane-4-yL) acetic acid derivatives
EP1375493A1 (en) 2002-06-17 2004-01-02 Dsm N.V. Process for the preparation of an dioxane acetic acid ester
GB0218781D0 (en) 2002-08-13 2002-09-18 Astrazeneca Ab Chemical process
DE60330050D1 (de) 2002-12-16 2009-12-24 Astrazeneca Uk Ltd Verfahren zur herstellung von pyrimidinverbindungen
GB0312896D0 (en) * 2003-06-05 2003-07-09 Astrazeneca Ab Chemical process
UY28501A1 (es) * 2003-09-10 2005-04-29 Astrazeneca Uk Ltd Compuestos químicos
GB0322552D0 (en) 2003-09-26 2003-10-29 Astrazeneca Uk Ltd Therapeutic treatment
GB0324791D0 (en) 2003-10-24 2003-11-26 Astrazeneca Ab Chemical process
GB0428328D0 (en) 2004-12-24 2005-02-02 Astrazeneca Uk Ltd Chemical process
GB0514078D0 (en) * 2005-07-08 2005-08-17 Astrazeneca Uk Ltd Chemical process
JP2008539278A (ja) * 2006-09-18 2008-11-13 テバ ファーマシューティカル インダストリーズ リミティド 結晶性ロスバスタチンカルシウム
TW200831469A (en) * 2006-12-01 2008-08-01 Astrazeneca Uk Ltd Chemical process
WO2010081861A1 (en) * 2009-01-14 2010-07-22 Krka, Tovarna Zdravil, D.D., Novo Mesto Process for the preparation of rosuvastatin
BRPI1005147A2 (pt) * 2009-01-15 2019-09-24 Egis Gyogyszergyar Nyilvanosan Muekoedoe Reszvenytarsasag processo de preparação de sais de rosuvastatina
HUP0900285A2 (en) 2009-05-07 2011-01-28 Egis Gyogyszergyar Nyilvanosan Mukoedoe Reszvenytarsasag Rosuvastatin salts and preparation thereof
WO2011074016A1 (en) 2009-12-17 2011-06-23 Matrix Laboratories Ltd Novel polymorphic forms of rosuvastatin calcium and process for preparation of the same
HU230737B1 (hu) 2010-11-16 2018-01-29 EGIS Gyógyszergyár Nyrt Eljárás rosuvastatin só előállítására
WO2012069394A1 (en) 2010-11-22 2012-05-31 Basf Se Multicomponent system of rosuvastatin calcium salt and sorbitol
DE202012011888U1 (de) 2011-04-18 2013-03-21 Basf Se Kristallines Mehrkomponentensystem von Rosuvastatin-Calciumsalz und Vanillin
WO2014050874A1 (ja) * 2012-09-27 2014-04-03 東和薬品株式会社 ロスバスタチンカルシウムの新規結晶形態およびその製造方法
RO129060B1 (ro) 2013-04-25 2014-11-28 Antibiotice S.A. Compoziţie farmaceutică stabilă cu rosuvastatină calcică amorfă
JP6596339B2 (ja) 2014-02-06 2019-10-23 株式会社エーピーアイ コーポレーション ロスバスタチンカルシウム及びその中間体の製造方法
PL3445751T3 (pl) 2016-04-18 2023-09-18 Morepen Laboratories Limited Nowa polimorficzna postać krystalicznej rozuwastatyny wapniowej i nowe procesy otrzymywania krystalicznej i amorficznej rozuwastatyny wapniowej
CN105837516B (zh) * 2016-05-16 2018-07-10 山东新时代药业有限公司 一种瑞舒伐他汀钙晶型及其制备方法
US11446757B2 (en) 2017-09-13 2022-09-20 Jfe Steel Corporation Double-sided friction stir welding method for metal sheets and double-sided friction stir welding device

Family Cites Families (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4645858A (en) * 1982-03-22 1987-02-24 G. D. Searle & Co. Pentanedioic acid derivatives
DE3741509A1 (de) * 1987-12-08 1989-06-22 Hoechst Ag Verfahren zur herstellung optisch aktiver 3-desmethylmevalonsaeurederivate sowie zwischenprodukte
EP0367895A1 (en) 1988-10-06 1990-05-16 Sandoz Ag Pyrimidinyl-substituted hydroxyacids, lactones and esters and pharmaceutical compositions containing them
US5026698A (en) * 1988-11-02 1991-06-25 Nissan Chemical Industries, Ltd. Thienopyridine type mevalonolactones
JP2648897B2 (ja) * 1991-07-01 1997-09-03 塩野義製薬株式会社 ピリミジン誘導体
WO1993008823A1 (en) 1991-11-06 1993-05-13 Tanabe Seiyaku Co., Ltd. Guanidinyl and related cell adhesion modulation compounds
US5278313A (en) * 1992-03-27 1994-01-11 E. R. Squibb & Sons, Inc. Process for the preparation of 1,3-dioxane derivatives useful in the preparation of HMG-COA reductase inhibitors
EP0577040B1 (de) * 1992-07-02 1997-09-24 Hoechst Aktiengesellschaft Verfahren zur Herstellung von (3R,5S)6-Hydroxy-3,5-0-isopropyliden-3,5-dihydroxy-hexansäure-tert.-butylester
ES2167587T3 (es) 1995-07-17 2002-05-16 Warner Lambert Co Forma cristalina de la sal hemicalcica del acido (r-(r*,r*))-2-(4-fluorofenil)-beta,delta-dihidroxi-5-(1-metiletil)-3-fenil-4-((fenilamino)carbonil)-1h-pirrol-1-heptanoico (atorvastatina).
FR2741620B1 (fr) 1995-11-28 1997-12-26 Oreal Procede de preparation de composes a groupement beta-hydroxy -delta-lactone analogues de la (+) compactine et de la (+) mevinoline
US6278001B1 (en) * 1995-11-28 2001-08-21 L'oréal Method for preparing (+) compactin and (+) mevinolin analog compounds having a β-hydroxy-δ-lactone grouping
EP0907639B1 (en) 1996-06-24 2003-03-12 Novartis AG Polymorphic compounds
SA99191255B1 (ar) 1998-11-30 2006-11-25 جي دي سيرل اند كو مركبات سيليكوكسيب celecoxib
CZ299566B6 (cs) * 1998-12-10 2008-09-03 Kaneka Corporation Zpusob výroby simvastatinu
GB9900339D0 (en) * 1999-01-09 1999-02-24 Zeneca Ltd Chemical compounds
GB9903472D0 (en) * 1999-02-17 1999-04-07 Zeneca Ltd Chemical process
WO2001022962A1 (en) 1999-09-30 2001-04-05 Merck & Co., Inc. Anti-hypercholesterolemic drug combination
PT1235799E (pt) 1999-11-17 2005-05-31 Teva Pharma Forma polimorfica de atorvastatina-calcio
GB0001621D0 (en) 2000-01-26 2000-03-15 Astrazeneca Ab Pharmaceutical compositions
GB0003305D0 (en) * 2000-02-15 2000-04-05 Zeneca Ltd Pyrimidine derivatives
AU2000254249A1 (en) 2000-03-28 2001-10-08 Biocon India Limited Synthesis of (r-(r*,r*))-2-(4-fluorophenyl)-beta,delta-dihydroxy-5-(1-
GB0011120D0 (en) * 2000-05-09 2000-06-28 Avecia Ltd Process
GB0011163D0 (en) 2000-05-10 2000-06-28 Astrazeneca Ab Chemical compound
NL1015744C2 (nl) * 2000-07-19 2002-01-22 Dsm Nv Werkwijze voor de bereiding van 2-(6-gesubstitueerde-1,3-dioxan-4-yl) azijnzuurderivaten.
PL361230A1 (en) 2000-10-05 2004-10-04 Biogal Gyogyszergyar Rt. Pravastatin sodium substantially free of pravastatin lactone and epi-pravastatin, and compositions containing same
US6777552B2 (en) * 2001-08-16 2004-08-17 Teva Pharmaceutical Industries, Ltd. Processes for preparing calcium salt forms of statins
HUP0303555A3 (en) 2000-11-16 2005-08-29 Teva Pharma Hydrolysis of [r(r
IL156055A0 (en) 2000-11-30 2003-12-23 Teva Pharma Novel crystal forms of atorvastatin hemi calcium and processes for their preparation as well as novel processes for preparing other forms
NL1017548C2 (nl) 2001-03-09 2002-09-10 Synthon Bv Een lactonisatie proces.
IN190564B (es) 2001-04-11 2003-08-09 Cadila Heathcare Ltd
WO2002098854A2 (en) 2001-06-06 2002-12-12 Bristol-Myers Squibb Company Process for preparing chiral diol sulfones and dihydroxy acid hmg coa reductase inhibitors
BR0211072A (pt) * 2001-07-13 2004-12-14 Astrazeneca Uk Ltd Processo para preparar um composto, composto, e, método para a preparação de um composto
NZ529913A (en) 2001-08-16 2005-03-24 Teva Pharma Processes for preparing calcium salt forms of statins
EP1423365A1 (en) 2001-08-22 2004-06-02 Ciba Specialty Chemicals Holding Inc. Process for the preparation of indole derivatives
JP2005512516A (ja) 2001-09-24 2005-05-12 メルク　エンド　カムパニー　インコーポレーテッド スタチン薬物の組合せのスクリーニング方法および選択方法
AR033485A1 (es) 2001-09-25 2003-12-26 Otsuka Pharma Co Ltd Sustancia medicinal de aripiprazol de baja higroscopicidad y proceso para la preparacion de la misma
EP1323717A1 (en) * 2001-12-27 2003-07-02 Dsm N.V. Process for the preparation of 2-(6-Substituted-1,3-Dioxane-4-yL) acetic acid derivatives
KR100511533B1 (ko) 2002-04-09 2005-08-31 임광민 키랄 중간체, 그의 제조방법 및 그를 이용한 HMG-CoA환원저해제의 제조방법
BR0311195A (pt) 2002-05-21 2005-02-22 Ranbaxy Lab Ltd Processo de preparação de rosuvastatina
EP1375493A1 (en) 2002-06-17 2004-01-02 Dsm N.V. Process for the preparation of an dioxane acetic acid ester
DE10228103A1 (de) 2002-06-24 2004-01-15 Bayer Cropscience Ag Fungizide Wirkstoffkombinationen
GB0218781D0 (en) 2002-08-13 2002-09-18 Astrazeneca Ab Chemical process
DE60330050D1 (de) 2002-12-16 2009-12-24 Astrazeneca Uk Ltd Verfahren zur herstellung von pyrimidinverbindungen
GB0312896D0 (en) * 2003-06-05 2003-07-09 Astrazeneca Ab Chemical process
US7563748B2 (en) 2003-06-23 2009-07-21 Cognis Ip Management Gmbh Alcohol alkoxylate carriers for pesticide active ingredients
UY28501A1 (es) * 2003-09-10 2005-04-29 Astrazeneca Uk Ltd Compuestos químicos
GB0321827D0 (en) * 2003-09-18 2003-10-15 Astrazeneca Uk Ltd Chemical compounds
GB0324791D0 (en) * 2003-10-24 2003-11-26 Astrazeneca Ab Chemical process
DE10352659B4 (de) 2003-11-11 2007-09-13 Ratiopharm Gmbh Verfahren zur Herstellung von Statinen und Tetrahydropyranonderivate zur Verwendung in dem Verfahren
WO2005054207A1 (en) * 2003-12-04 2005-06-16 Glenmark Pharmaceuticals Limited Process for the preparation of pyrimidine derivatives
US7241800B2 (en) * 2004-03-17 2007-07-10 Mai De Ltd. Anhydrous amorphous form of fluvastatin sodium
US7161004B2 (en) * 2004-06-21 2007-01-09 Dr. Reddy's Laboratories Limited Processes to produce intermediates for rosuvastatin
WO2006000020A1 (en) 2004-06-29 2006-01-05 European Nickel Plc Improved leaching of base metals
GB0428328D0 (en) * 2004-12-24 2005-02-02 Astrazeneca Uk Ltd Chemical process
EP1895898B1 (en) 2005-06-29 2011-02-16 Compumedics Limited Sensor assembly with conductive bridge
TW200831469A (en) * 2006-12-01 2008-08-01 Astrazeneca Uk Ltd Chemical process

Also Published As

Publication number Publication date
AU2004270467B2 (en) 2008-08-21
US20130225622A1 (en) 2013-08-29
NZ545785A (en) 2010-03-26
RU2363697C2 (ru) 2009-08-10
PL1663989T3 (pl) 2009-08-31
MY142615A (en) 2010-12-15
AU2004270467B8 (en) 2008-09-18
IS8385A (is) 2006-03-30
TWI370817B (en) 2012-08-21
NO20061181L (no) 2006-03-29
CN1878760A (zh) 2006-12-13
AU2004270467A1 (en) 2005-03-17
CO5670355A2 (es) 2006-08-31
CY1109173T1 (el) 2014-07-02
US8436167B2 (en) 2013-05-07
US20100222373A1 (en) 2010-09-02
IL174073A (en) 2014-03-31
PT1663989E (pt) 2009-06-09
CA2537962C (en) 2012-10-23
DE602004020640D1 (de) 2009-05-28
CA2537962A1 (en) 2005-03-17
HRP20090335T1 (en) 2009-07-31
UA85062C2 (uk) 2008-12-25
MXPA06002761A (es) 2006-12-14
RU2006111354A (ru) 2007-10-27
IL174073A0 (en) 2006-08-01
DK1663989T3 (da) 2009-07-06
CN1878760B (zh) 2011-11-09
JP2007505090A (ja) 2007-03-08
SI1663989T1 (sl) 2009-08-31
US20060293355A1 (en) 2006-12-28
WO2005023779A1 (en) 2005-03-17
BRPI0414236A (pt) 2006-10-31
EP1663989B1 (en) 2009-04-15
EP1663989A1 (en) 2006-06-07
IS2689B (is) 2010-10-15
SA04250297B1 (ar) 2008-11-18
NO336358B1 (no) 2015-08-03
HK1090361A1 (en) 2006-12-22
ATE428701T1 (de) 2009-05-15
ES2324042T3 (es) 2009-07-29
TW200526595A (en) 2005-08-16
KR20070019943A (ko) 2007-02-16
AR045628A1 (es) 2005-11-02
US20120059022A1 (en) 2012-03-08

Similar Documents

Publication Publication Date Title
UY28501A1 (es) Compuestos químicos
IS8478A (is) Aðferð til að framleiða kalsíumsalt rósúvatatín (E)-7-[4-(4-flúorfenýl)-6-ísóprópýl-2-[metýl(metýlsúlfónýl)amínó]pýrimídín-5-ýl] (3R,5S)-3,5-díhýdroxýhept-6-enósýru og kristölluð milliefni þess
EA200500721A1 (ru) Пиримидины, ингибирующие chk, pdk и акт, их получение и применение в качестве лекарственных средств
SV2006002232A (es) Inhibidores bace ref. x-16940
EA200801291A1 (ru) Карбониламинопирролопиразолы в качестве эффективных ингибиторов киназ
ECSP099044A (es) Compuestos de pirimido fusionados
BR0306957A (pt) Herbicidas
DK1817301T3 (da) Forstærkere af glutamat-receptorer
BRPI0510177B8 (pt) composto, composição farmacêutica e uso do mesmo
ECSP066540A (es) Pentanoles transpuestos, un método para prepararlos y su uso como antiinflamatorios
EA201000494A1 (ru) Новые гидрокси-8-гетероарилфенантридины и их применение в качестве ингибиторов pde4
BRPI0514681A (pt) derivados de pirimidina
BR0214891A (pt) Herbicidas
EA200701396A1 (ru) Триазолофталазины в качестве ингибиторов pde-2
EA200801560A1 (ru) Бифенилкарбоксамиды
AR029228A1 (es) Sal cristalina de acido (e)-7-[4-(4-fluorofenil)-6-isopropil-2-[metil(metilsulfonil)amino]pirimidin-5-il]-(3r,5s)-3,5-dihidroxihept-6-enoico, composicion farmaceutica que la comprende, proceso para su elaboracion y usos de la misma
ATE365740T1 (de) Substituierte pyrazolopyrimidine
BRPI0312649A2 (pt) compostos, composições farmacêuticas contendo os mesmos, e processos de uso para os mesmos.
NO20061324L (no) Polymorfe former av en kjent antihyperlinemisk forbindelse
BRPI0509926A (pt) imidazóis
DK1567482T3 (da) Fremgangsmåde til fremstilling af phenylmalonsyre-dinitriler
CL2004001678A1 (es) Compuestos derivados de oxazolidinona; composicion farmaceutica; y uso de los compuestos como agentes bacterianos.
UY27902A1 (es) Derivados aldehido de polietilenglicol
PL1704144T3 (pl) Sposób wytwarzania soli wapniowej kwasu (E)-7-[4-(4-fluorofenylo)-6-izopropylo-2-[metylo(metylosulfonylo)amino]pirymidyn-5-ylo](3R,5S)-3,5-dihydroksy-6-heptenowego
UY28653A1 (es) N-alquil pirroles como inhibidores de la hmg-coa reductasa

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20150604